Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Continuous positive airway pressure (CPAP) and BiPAP (bi-level) therapy are used to treat sleep apnea. CPAP is the most ...

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that ... But, in July 2024, GM-CSF inhalation therapy for autoimmune pulmonary proteinosis finally became available under the ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

Until now, OSA treatment has focused on mechanical support during sleep in the form of positive airway pressure (PAP) therapy. "Today's approval marks the first drug treatment option for certain ...

After one year, 42% of Zepbound users without PAP therapy and 50% with PAP therapy achieved remission or mild, non-symptomatic OSA, compared to 16% and 14% in placebo groups, respectively.